Gilead (GILD) Issues Strong '7977 Update, Shares Move Higher
Get Alerts GILD Hot Sheet
Join SI Premium – FREE
Shares of Gilead Sciences, Inc. (Nasdaq: GILD) are moving higher Friday following positive data related to its experimental hepatitis C (HCV) treatments.
On the company's fourth-quarter earnings conference call late Thursday, Gilead's scientific chief Norbert Bischofberger said trials of PSI-7977 in patients with genotype 1 HCV showed no signs of the virus after being on the drug for four weeks.
PSI-7977 was said to cure patients with genotypes 2 and 3, according to earlier studies.
Competitors in the field include Merck (NYSE: MRK), Vertex Pharma (NYSE: VRTX), Bristol-Myers Squibb (NYSE: BMY), Idenix Pharma (Nasdaq: IDIX) and Achillion Pharma (Nasdaq: ACHN).
A number of analysts issued comments on Gilead following the call. For more color, click here.
Gilead shares last traded at $54.40, up 10.3 percent from Thursday's close.
On the company's fourth-quarter earnings conference call late Thursday, Gilead's scientific chief Norbert Bischofberger said trials of PSI-7977 in patients with genotype 1 HCV showed no signs of the virus after being on the drug for four weeks.
PSI-7977 was said to cure patients with genotypes 2 and 3, according to earlier studies.
Competitors in the field include Merck (NYSE: MRK), Vertex Pharma (NYSE: VRTX), Bristol-Myers Squibb (NYSE: BMY), Idenix Pharma (Nasdaq: IDIX) and Achillion Pharma (Nasdaq: ACHN).
A number of analysts issued comments on Gilead following the call. For more color, click here.
Gilead shares last traded at $54.40, up 10.3 percent from Thursday's close.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- European stocks rise, helped by positive global sentiment; NatWest gains
- Amundi surges as on bigger-than-expected profit, record AUM
Create E-mail Alert Related Categories
Corporate News, Insiders' BlogRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!